Idelvion becomes first and only Factor IX therapy with 21-day prophylactic dosing for treating haemophilia B. CSL Behring.
CSL Behring announced that the European Medicines Agency (EMA) has approved the new Summary of Product Characteristics, which includes information about new, extended dosing options for Idelvion [albutrepenonacog… read more.